Amicus Therapeutics
FOLD
FOLD was delisted on the 24th of April, 2026.
251 hedge funds and large institutions have $3.93B invested in Amicus Therapeutics in 2020 Q3 according to their latest regulatory filings, with 43 funds opening new positions, 77 increasing their positions, 94 reducing their positions, and 19 closing their positions.
161% more call options, than puts
Call options by funds: $38.3M | Put options by funds: $14.7M
126% more first-time investments, than exits
New positions opened: 43 | Existing positions closed: 19
11% more funds holding
Funds holding: 227 → 251 (+24)
1.89% less ownership
Funds ownership: 109.41% → 107.52% (-1.9%)
8% less capital invested
Capital invested by funds: $4.25B → $3.93B (-$324M)
18% less repeat investments, than reductions
Existing positions increased: 77 | Existing positions reduced: 94
25% less funds holding in top 10
Funds holding in top 10: 8 → 6 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$40.3M |
| 2 |
Janus Henderson Group
London,
|
+$33.7M |
| 3 |
UBS AM
Chicago,
Illinois
|
+$17.7M |
| 4 |
William Blair Investment Management
Chicago,
Illinois
|
+$14.1M |
| 5 |
Loomis, Sayles & Company
Boston,
Massachusetts
|
+$13.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$51.8M |
| 2 |
RG
Redmile Group
San Francisco,
California
|
-$27.2M |
| 3 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
-$23.9M |
| 4 |
DM
Deerfield Management
New York
|
-$21.4M |
| 5 |
State Street
Boston,
Massachusetts
|
-$19.7M |
FOLD Hedge Fund Activity: Q3 2020 in Review
251 of the 4,970 institutional investors tracked by Wall St. Rank reported a position in Amicus Therapeutics (FOLD) for Q3 2020, worth a combined $3.93B — down 7.6% from $4.25B a quarter earlier.
Buyers outnumbered sellers: 43 funds opened new FOLD positions and 19 closed out — a net gain of 24 holders — while 77 added to existing stakes and 94 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $40.3M. The largest seller was Fidelity Investments, cutting an estimated $51.8M.
- 251 institutional investors held Amicus Therapeutics (FOLD) as of Q3 2020, up from 227 in Q2 2020.
- Funds reported $3.93B of Amicus Therapeutics stock for Q3 2020, down 7.6% quarter-over-quarter.
- 43 funds opened new Amicus Therapeutics positions in Q3 2020 and 19 closed out, a net change of +24 holders.
- The largest Amicus Therapeutics buyer in Q3 2020 was Morgan Stanley, an estimated $40.3M added.
- The largest Amicus Therapeutics seller in Q3 2020 was Fidelity Investments, an estimated $51.8M sold.
Based on aggregated 13F filings for Q3 2020.